Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Personalized Medicine and its Impact in the Clinic

Klaus Pantel's Biography



Klaus Pantel, Chairman, Department of Tumor Biology, University Medical Center Hamburg-Eppendorf

Prof. Klaus Pantel graduated in 1986 from Cologne University in Germany and completed his thesis on mathematical modelling of hematopoiesis in 1987. After his postdoctoral period in the USA on hematopoietic stem cell regulation (Wayne State University, Detroit), he performed research on cancer micrometastasis at the Institute of Immunology, University of Munich for 10 years. Currently, Prof Pantel is Chairman of the Institute of Tumour Biology at the University Medical Center Hamburg-Eppendorf. The institute is part of the University Cancer Center Hamburg (UCCH). The pioneer work of Prof Pantel in the field of cancer micrometastasis, circulating tumor cells and circulating nucleic acids (ctDNA, microRNAs) is reflected by more than 300 publications in excellent high ranking biomedical and scientific journals (incl. NEJM, Lancet, Nature Journals, Cancer Cell, PNAS, JCO, JNCI, Cancer Res.) and has been awarded recently (AACR Outstanding Investigator Award 2010, German Cancer Award 2010, ERC Advanced Investigator Grant 2011). Moreover, Prof Pantel was co-ordinator of the FP6 EU STREP “DISMAL” (Disseminated Malignancies, www.dismal-project.eu), coordinates now the European TRANSCAN group “CTC-SCAN” and the EU IMI Network Project “CANCER-ID” (www.cancer-id.eu) and serves on the Editorial Boards of international cancer journals (e.g., Clin. Cancer Res., Breast Cancer Res., Cancer Res.).

Klaus Pantel Image

Liquid Biopsy: Detection and Molecular Characterization of Circulating Tumor Cells and DNA

Thursday, 8 October 2015 at 09:00

Add to Calendar ▼2015-10-08 09:00:002015-10-08 10:00:00Europe/LondonLiquid Biopsy: Detection and Molecular Characterization of Circulating Tumor Cells and DNAPersonalized Medicine and its Impact in the Clinic in Hanover, GermanyHanover, GermanySELECTBIOenquiries@selectbiosciences.com

The analysis of CTCs, ctDNA and circulating microRNAs may provide complementary information as “liquid biopsy”. This information can be used as companion diagnostics to improve the stratification of therapies and to obtain insights into therapy-induced selection of cancer cells.


Add to Calendar ▼2015-10-07 00:00:002015-10-08 00:00:00Europe/LondonPersonalized Medicine and its Impact in the ClinicPersonalized Medicine and its Impact in the Clinic in Hanover, GermanyHanover, GermanySELECTBIOenquiries@selectbiosciences.com